PulmoSIM Planning to Bring PAH Therapy, PT001, Into Clinical Testing

PulmoSIM Planning to Bring PAH Therapy, PT001, Into Clinical Testing

301269

PulmoSIM Planning to Bring PAH Therapy, PT001, Into Clinical Testing

PulmoSIM Therapeutics has joined with scientists at National Jewish Health hospital and Brown University to advance PT001, its investigational and potentially disease-modifying therapy for pulmonary arterial hypertension (PAH), into clinical trials. The partnership follows PT001 being designated an orphan drug by the U.S. Food and Drug Administration (FDA). Orphan drug status aims to encourage the development of therapies for rare and serious diseases, through benefits such as seven years of market exclusivity if granted approval and exemption from FDA…

You must be logged in to read/download the full post.